DongKoo Bio & Pharma Co., Ltd. Logo

DongKoo Bio & Pharma Co., Ltd.

Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.

006620 | KO

Overview

Corporate Details

ISIN(s):
KR7006620009
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로 114, B동 14층, 송파구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

DongKoo Bio & Pharma Co., Ltd. is a pharmaceutical company founded in 1970 that engages in the research, development, manufacturing, and sale of medical products. The company is a recognized leader in the dermatology prescription market and also offers a portfolio of products including antihistamines, probiotics, and treatments for gum disease. Strategically expanding beyond traditional pharmaceuticals, the company pursues an 'Open Innovation' model to develop differentiated pipelines and invest in future technologies, with a focus on biotechnology and stem cell-based therapies. It operates with world-class research centers and GMP (Good Manufacturing Practice) certified facilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.1 MB
2025-07-02 00:00
M&A Activity
합병등종료보고서(합병)
Korean 16.5 KB
2025-06-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-04-30 00:00
M&A Activity
주요사항보고서(회사합병결정)
Korean 72.2 KB
2025-04-30 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 5.2 KB
2025-04-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-04-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-03-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-03-31 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 32.1 KB
2025-03-27 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.7 KB
2025-03-27 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.7 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 17.3 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.3 KB

Automate Your Workflow. Get a real-time feed of all DongKoo Bio & Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKoo Bio & Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKoo Bio & Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730

Talk to a Data Expert

Have a question? We'll get back to you promptly.